FDA delays nicotine pouch fast-track approvals in US

The U.S. Food and Drug Administration (FDA) has slowed decisions on several nicotine pouch applications that were being considered under a fast-track pathway, citing concerns about potential harm to youth and people who do not currently use nicotine. The delayed authorizations include products linked to Philip Morris International and British American Tobacco, according to the source material.

The postponement affects the world’s largest market for smoking alternatives, which the source material values at approximately $22 billion. The FDA’s caution reflects internal scientific debate about whether the evidence supporting expedited clearance is as straightforward as expected for the agency’s pilot approach.

The fast-track effort stems from a pilot program initiated in 2025 to speed up reviews of new tobacco product applications. Under that program, decisions for certain labels were expected by the end of December 2025, but several prominent nicotine pouch brands are still awaiting outcomes.

In December, the FDA authorized six nicotine pouch products sold under Altria’s on! PLUS brand. However, applications for three other major brands remain pending, according to the source material, underscoring that the pilot program has not produced uniform outcomes across companies and product lines.

Agency scientists are described as weighing two competing public-health considerations. On one side is the possibility that nicotine pouches could help some smokers move away from more harmful forms of tobacco; on the other is the risk that easier access and broader marketing could encourage nicotine initiation among non-smokers and minors.

Nicotine pouches are described as the fastest-growing nicotine product category in the U.S., with millions of users. The source material highlights the scale of demand by pointing to Philip Morris International’s Zyn sales: 794 million cans sold in the U.S. in 2025, more than double the company’s 2023 sales.

The FDA’s stance is also shaped by its view of nicotine’s health profile. The agency considers nicotine products highly addictive and harmful to developing brains, and it has pointed to its annual survey showing that nicotine pouch use among middle and high school students is rising, even if overall levels remain low.

For companies seeking U.S. authorization, the delays introduce uncertainty around product rollout timelines and the pace of growth in a key market for smoking alternatives. The pending decisions also signal that, even within an accelerated review framework, the FDA may apply heightened scrutiny where youth exposure and non-user uptake are central concerns.